Anti-tumor angiogenesis strategies frequently employ pharmacological agents that target vascular endothelial growth factor (VEGF) to impede its binding to receptors, thereby inhibiting the formation of blood vessels that support tumor growth. Here, VEGFA is linked to neoplasm.